Actavis sells infrastructure to India's Aruobindo

Share this article:

Generics firm Actavis announced Friday that it was selling its pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and dossier license rights to India's Aurobindo Pharma, which has been on a path of expanding its European footprint.

Friday's announcement follows Bloomberg's report that Actavis is looking to extricate itself from China. CEO Paul Bisaro told Bloomberg at the JP Morgan Healthcare conference that China's business climate is too difficult to continue to operate in. “It wasn't worth the aggravation, the frustration or the concern.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.